A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

This trial is testing whether using the chemotherapy regimen NALIRIFOX in combination with ablative dose radiation therapy (AD-XRT) and the standard chemotherapy drug capecitabine is an effective treatment approach for people with locally advanced or borderline resectable pancreatic ductal adenocarcinoma (PDAC) before surgery. The researchers will also look at whether the sequence of the treatment approach (NALIRIFOX + ADXRT and capecitabine followed by surgery, when it is possible) is effective and causes few or mild side effects in participants. An important purpose of it is to see how it treatment (NALIRIFOX + AD-XRT and capecitabine) affects participants' quality of life.

Simplified from trial records by PatientMatch.

What you may be asked to do

• 1.Take AD-XRT and Capecitabine
• 2.Take NALIRIFOX